3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
5
Melanoma
4
Glioblastoma
4
Carcinoma
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasms
2
Fibrolamellar hepatocellular carcinoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Interventions
pembrolizumab
44
Gemcitabine
23
enfortumab vedotin
21
Nivolumab
20
Cisplatin
17
avelumab
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
atezolizumab
13
Specimen Handling
12
Docetaxel
11
sacituzumab govitecan
9
Paclitaxel
8
Ipilimumab
8
durvalumab
6
Mitomycin
5
Fluorodeoxyglucose F18
5
cabozantinib
4
Taxes
4
toripalimab
3
pemigatinib
3
erdafitinib
3
X-Rays
3
Radiosurgery
3
Platinum
3
Pemetrexed
3
Immunoglobulin G
3
CTLA-4 Antigen
3
Biopsy
3
ALT-803
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
poly ICLC
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled